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Abstract
Background: Point mutations resulting in reduced factor VIII (FVIII) binding to von Willebrand factor (VWF) are an important
cause of mild/moderate hemophilia A. Treatment includes desmopressin infusion, which concomitantly increases VWF and
FVIII plasma levels, apparently from storage pools containing both proteins. The source of these VWF/FVIII co-storage pools
and the mechanism of granule biogenesis are not fully understood.
Methodology/Principal Findings: We studied intracellular trafficking of FVIII variants implicated in mild/moderate
hemophilia A together with VWF in HEK293 cells and primary endothelial cells. The role of VWF binding was addressed
using FVIII variants displaying reduced VWF interaction. Binding studies using purified FVIII proteins revealed moderate
(Arg2150His, Del2201, Pro2300Ser) to severe (Tyr1680Phe, Ser2119Tyr) VWF binding defects. Expression studies in HEK293
cells and primary endothelial cells revealed that all FVIII variants were present within VWF-containing organelles.
Quantitative studies showed that the relative amount of FVIII storage was independent of various mutations. Substantial
amounts of FVIII variants are co-stored in VWF-containing storage organelles, presumably by virtue of their ability to interact
with VWF at low pH.
Conclusions: Our data suggest that the potential of FVIII co-storage with VWF is not affected in mild/moderate hemophilia
A caused by reduced FVIII/VWF interaction in the circulation. These data support the hypothesis that Weibel-Palade bodies
comprise the desmopressin-releasable FVIII storage pool in vivo.
Citation: van den Biggelaar M, Bouwens EAM, Voorberg J, Mertens K (2011) Storage of Factor VIII Variants with Impaired von Willebrand Factor Binding in
Weibel-Palade Bodies in Endothelial Cells. PLoS ONE 6(8): e24163. doi:10.1371/journal.pone.0024163
Editor: Dimas Tadeu Covas, University of Sao Paulo–USP, Brazil
Received April 4, 2011; Accepted August 1, 2011; Published August 31, 2011
Copyright:  2011 van den Biggelaar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: m.vandenbiggelaar@sanquin.nl
Introduction
Factor VIII (FVIII) is an essential cofactor in the factor Xa
(FXa) generating complex by accelerating the factor IXa (FIXa)
mediated-conversion of factor X (FX) into activated factor X
(FXa) [1]. The FVIII translation product consists of a 19 amino
acid signal peptide followed by a 2332 amino acid precursor
protein that is organized in a distinct domain structure: A1-a1-A2-
a2-B-a3-A3-C1-C2. Due to intracellular proteolytic processing,
FVIII circulates in plasma as a heterodimer consisting of a 90–220
kDa heavy chain (A1-a1-A2-a2-B) and a 80 kDa light chain (a3-
A3-C1-C2). The heavy chain and light chain of FVIII remain
associated through a variety of interactions, some of which are
metal-ion dependent [2]. In the circulation, FVIII travels in
complex with its carrier protein von Willebrand factor (VWF),
preventing premature clearance and proteolytic degradation of
FVIII [1].
A defect in the gene encoding for FVIII results in the X-
chromosome linked bleeding disorder hemophilia A. Large
deletions, frame-shifts, premature stop codons or intron inversions
are most commonly associated with severe hemophilia A and
result in functional FVIII levels below 1% [3]. Severe hemophilia
A patients are treated with on-demand or prophylactic protein
replacement therapy using plasma derived or recombinant FVIII
concentrates. Point mutations and small in-frame insertions or
deletions in the FVIII gene generally result in a moderate or mild
hemophilia A phenotype with circulating functional FVIII plasma
levels between 1–5% and 5–30% respectively [3]. The molecular
mechanisms that underlie moderate and mild hemophilia A
include defects with respect to biosynthesis, impaired secretion,
altered interaction with factor IXa, reduced binding to phospho-
lipid membranes, impaired thrombin activation, impaired stability
in the circulation or a reduced ability to associate with VWF in
plasma [3,4]. In addition to protein replacement therapy, mild or
moderate hemophilia A patients can be treated with infusions of
the vasopressin analogue desmopressin (DDAVP) [5,6].
Administration of DDAVP releases both VWF and FVIII in the
circulation [7]. The source of DDAVP-releasable VWF and FVIII
has not been established. However, several lines of evidence
suggest that FVIII and VWF are synthesized and stored within the
same cell [8,9]. This view is supported by the observation that
in vitro co-expression of VWF and FVIII results in storage of FVIII
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24163in VWF-containing organelles [10-15]. Lung microvascular
endothelial cells and liver sinusoidal endothelial cells both
synthesize VWF and FVIII in vivo [16–18]. Recently, it has been
shown that endothelial cells from several vascular beds, including
the hepatic sinusoid and pulmonary vascular circulation, can
synthesize and secrete FVIII [19].
We have previously demonstrated that FVIII trafficking to
VWF-containing storage organelles is independent of high-
affinity binding to VWF [13,15]. VWF 2N variants that do not
bind FVIII are still able to induce FVIII storage in WPBs [15],
providing a rationale for the observed DDAVP-induced release of
FVIII and VWF in type 2N VWD patients [20]. It remains
unknown whether, in addition to type 2N VWD patients, co-
storage of FVIII and VWF may also underlie the DDAVP-
mediated increase of FVIII plasma levels in patients suffering
from mild/moderate hemophilia. The aim of this study was
therefore to analyze VWF co-storage for a panel of FVIII variants
associated with mild/moderate hemophilia A due to reduced
binding to VWF. For these studies, we selected 5 FVIII variants
that have been established to cause mild to moderate hemophilia
A due to reduced binding to VWF [21–24]. We analyzed
targeting of these FVIII variants to VWF-containing granules in
heterologous HEK293 cells as well as in primary endothelial cells.
Our results demonstrate that, despite impaired complex assembly
with VWF, all FVIII variants retain their capability to traffic to
VWF-containing organelles. These data support the hypothesis
that FVIII-containing WPBs represent a desmopressin-releasable
storage pool of VWF and FVIII in vivo.
Results
Expression of FVIII-YFP variants in HEK293 cells
To address the role of amino acid substitutions that cause mild/
moderate hemophilia A in the intracellular trafficking of FVIII, we
have created 5 FVIII variants in B-domain deleted FVIII-YFP
that have been established to cause mild to moderate hemophilia
A due to reduced binding to VWF [21–24], including single
Tyr1680Phe, Ser2119Tyr, Arg2150His, Del2201 or Pro2300Ser
substitutions. The effect of the hemophilic replacements on
secretion of FVIII was studied. FVIII-YFP variants were expressed
in HEK293 cells stably expressing VWF-CFP and FVIII levels in
conditioned medium were quantified based on heterodimer
ELISA and chromogenic activity (Table 1). Transient expression
of wild type FVIII-YFP resulted in significant levels of FVIII in
conditioned medium (5.060.4 pmol FVIII:Ag/1610
6 cells per
72 hours) (Table 1). Levels of FVIII-YFP variants carrying a
Tyr1680Phe and Ser2119Tyr replacement or a deletion of
Ala2201 were approximately 50% reduced whereas levels of
FVIII-YFP variants carrying an Arg2150His or Pro2300Ser were
more than 10-fold reduced (Table 1). None of the variants showed
an apparent secretion defect (Figure 3, see below). The levels of
VWF were not affected (6.760.8 pmol VWF/1610
6 cells per
72 hours).
Purification of FVIII-YFP variants produced by HEK293
cells
To address the ability of the FVIII variants to associate with
VWF, FVIII-YFP variants were purified from the conditioned
medium of HEK293 cell-lines expressing FVIII-YFP variants (in
absence of VWF) using immunoaffinity chromatography. Due to
low production levels, the Arg2150His variant could only be
purified partially. After purification, the values for the specific
activity of all other variants were at least .2000 U/mg (Table 1).
SDS-PAGE analysis demonstrated that all these FVIII variants
were processed and secreted predominantly as a heterodimer with
virtual absence of single chain FVIII (Figure 1A).
Pseudo-equilibrium FVIII/VWF binding
Binding of FVIII-YFP variants, including the partially purified
Arg2150His variant, to VWF was analyzed under pseudo-
equilibrium conditions (Figure 1B) [13]. As described previously
[13], FVIII-YFP readily bound to VWF with high affinity in the
subnanomolar range (Figure 1B). All FVIII-YFP variants demon-
strated a binding defect, in the following qualitative ranking:
Arg2150His.Del2201.Pro2300Ser.Tyr1680Phe=Ser2119Tyr.
While variants carrying a Tyr1680Phe or Ser2119Tyr replacement
demonstrated a severe reduction in VWF binding, appreciable
binding was observed for the variants carrying an Arg2150His and
Pro2300Ser replacement or deletion of Ala2201 (Figure 1B).
Surface plasmon resonance analysis of FVIII/VWF binding
We further used Surface Plasmon resonance (SPR) analysis to
study binding of individual FVIII-YFP to purified recombinant
VWF containing high molecular weight multimers. The Ar-
g2150His variant could not be analyzed as this variant was only
partially purified. Representative SPR experiments are shown in
Figure 1C and data are summarized in Figure 1D. SPR data
demonstrated that wild type FVIII-YFP readily bound to VWF
(Figure 1C curve a). All FVIII-YFP variants showed reduced
binding to VWF (Figure 1C curve b–e). Variants carrying a
Tyr1680Phe and Ser2119Tyr replacement demonstrated a severe
reduction in VWF binding. For these variants, some residual
binding occurred which was rapidly lost during the dissociation
phase (Figure 1C curve b,c). Variants carrying a Pro2300Ser
replacementora deletion ofAla2201 demonstrated a bindingdefect
that was less pronounced (Figure 1C curve d,e). In addition, binding
proved partially irreversible, presumably due to rapid rebinding of
FVIII to the immobilized VWF immediately following dissociation.
Rapid rebinding often implies that association is mass transport
limited, which prohibits calculation of reliable binding kinetics [25].
Therefore, SPR data were used to qualitatively compare the
different variants (Figure 1D). In agreement with the binding assay
under pseudo-equilibrium conditions (Figure 1B), all FVIII-YFP
Table 1. Specific activity and production levels of FVIII
variants.
FVIII-YFP Production levels Specific activity of
variant purified variants
pmol FVIII/1610
6 cells/72 hours FVIII activity (U)/
antigen activity mg protein
wild type 5.060.3 4.160.4 3.260.3610
3
Tyr1680Phe 3.960.4 2.360.5 2.160.2610
3
Ser2119Tyr 3.260.4 2.060.2 3.660.3610
3
Arg2150His 0.360.1 0.360.1 1.260.1610
3
Del2201 2.760.1 2.060.1 2.160.1610
3
Pro2300Ser 0.360.1 0.360.1 3.460.2610
3
Production levels of FVIII: Ag were quantified by heterodimer ELISA using CLB-
CAg9 and CLB-CAg117 and FVIII activity levels were quantified by chromogenic
activity. Specific activity of purified FVIII-YFP variants was evaluated as the FVIII
activity as determined by chromogenic assay (in U) per mg of protein as
determined by Bradford assay. Each value represents the mean 6 SD of at least
three measurements.
doi:10.1371/journal.pone.0024163.t001
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ranking: Del2201.Pro2300Ser.Tyr1680Phe=Ser2119Tyr.
FVIII-VWF co-trafficking in HEK293 cells
We subsequently addressed the subcellular localization of FVIII
variants in HEK293 cells. Wild type FVIII-YFP staining is
associated with the secretory pathway at the level of the trans-Golgi
network and endoplasmatic reticulum [13]. Expression of
hemophilic FVIII-YFP variants resulted in a similar localization
(data not shown). As reported before [13], FVIII-YFP was
observed in VWF-containing organelles in cells expressing VWF-
CFP (Figure 2). Co-expression studies with P-selectin revealed that
the VWF/FVIII-containing organelles retained the ability to
recruit P-selectin. FVIII-YFP variants that demonstrate a
moderate (Del2201) or severely reduced binding to VWF
(Tyr1680Phe and Ser2119Tyr) were still able to co-traffic to
VWF/P-selectin-containing granules (Figure 2). In addition, the
FVIII-YFP variants carrying an Arg2150His or Pro2300Ser are
stored in VWF/P-selectin-containing granules despite a moderate
reduction in VWF binding and a more than 10-fold reduction in
FVIII levels in conditioned medium (Figure 2).
Storage of FVIII-YFP variants in VWF-containing granules
in HEK293 cells
So far, we have analyzed targeting of FVIII and VWF on a
qualitative level. Our findings indicate that FVIII variants
displaying a strongly reduced affinity for VWF can enter VWF-
containing granules. We subsequently explored whether the
amount of FVIII stored within VWF-containing granules depends
on the affinity of FVIII for VWF. To address FVIII storage in
VWF-containing granules in a more quantitative manner, we
analyzed the amount of VWF-CFP containing vesicles that also
Figure 1. Binding of purified fluorescent FVIII-YFP variants to VWF. Letters represent wild type FVIII-YFP (a) Tyr1680Phe, (b) Ser2119Tyr, (c)
Del2201 (d), Pro2300Ser (e) and Arg2150His (f). (A) Purified protein preparations were analyzed by 7.5% sodium dodecylsulfate polyacrylamide gel
electrophoresis under reducing conditions followed by silver staining. HC = heavy chain. LC= light chain. YFP = yellow fluorescent protein. (B)
Pseudo-equilibrium binding of FVIII-YFP variants to VWF using an ELISA-based format was performed. The amount of FVIII bound to VWF was plotted
against the amount of FVIII added. Data were analyzed by non-linear regression using a standard hyperbola. Each value represents the mean of three
experiments. (C) SPR analysis of FVIII binding to VWF. FVIII variants were passed over a chip to which 22 fmol/mm
2 recombinant wild type VWF was
coupled in a buffer containing 150 mM NaCl, 5 mM CaCl2, 5% (v/v) Glycerol, 0.005% (v/v) Tween 20 and 20 mM Hepes (pH 7.4) at 25uC with a flow
rate of 20 mL/min. Association and dissociation phase were both followed for 240 seconds. Shown is the average curve of three injections of 2.5 nM
of (each) FVIII variant. (D) Percentage of binding was calculated relative to wild type FVIII after 235 seconds of association. Values represent the mean
6 SEM of at least 6 injections (1–10 nM FVIII variants).
doi:10.1371/journal.pone.0024163.g001
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replacement, 80–100% of VWF-containing vesicles contained
FVIII-YFP (Figure 3A). This observation indicates that targeting
of FVIII variants to VWF-containing vesicles is independent of
their affinity for VWF. In addition, we performed subcellular
fractionations followed by density gradient centrifugation. Ho-
mogenates of transfected HEK293 cells were subjected to density
gradient centrifugation and the amount of VWF and FVIII in the
various fractions was determined by ELISA. Representative
fractionations are shown in Figure 3B-G. The dense fraction
containing the WPB-like organelles corresponds with fractions 4–
9, whereas the second peak contains the subcellular fractions
derived of organelles of the secretory pathway (ER, Golgi, trans-
Golgi network) and constitutively released vesicles [26]. For wild
type FVIII-YFP, 2166% of FVIII-YFP antigen and 1665% of
VWF-CFP antigen was found in the dense fraction of the cell
(Table 2). To exclude that presence of the fluorescent YFP and
CFP moieties influences targeting, subcellular fractionations were
also performed using untagged FVIII and VWF variants. For
untagged FVIIIdB, 17% was targeted to the dense fraction of the
cell containing wild type VWF (data not shown). This indicates
that the YFP/CFP moieties do not contribute to targeting of FVIII
and VWF. Storage of all FVIII-YFP variants in VWF-CFP
containing granules was quantified. As expected, total intracellular
FVIII antigen levels were reduced for the variants carrying an
Arg2150His or Pro2300Ser replacement (Figure 3C,D). However,
despite the reduced FVIII levels, a significant portion of the
intracellular FVIII antigen was stored within the dense fraction of
the cell. In addition, FVIII-YFP variants that display a moderate
(Del2201) or severe reduction in VWF binding (Tyr1680Phe or
Ser2119Tyr), are clearly stored in the fraction corresponding with
VWF-containing granules (Figure 3E,F,G). These data demon-
strate that substantial amounts of mild/moderate hemophilia A
causing FVIII variants can be stored in VWF-containing storage
organelles (Table 2).
FVIII-VWF co-trafficking in Blood Outgrowth Endothelial
Cells (BOECs)
To validate the use of HEK293 cells as a model system, we also
analyzed trafficking of FVIII-YFP variants in genuine endothelial
cells. Previous studies have shown that BOEC provide an excellent
model for studying the biosynthesis of VWF as well as targeting of
FVIII to WPBs [14,27]. As was demonstrated for HEK293 cells, all
FVIII-YFP variants were stored in organelles that also contained
VWF. We conclude that FVIII trafficking to WPBs in BOECs is
independent of the absence of high-affinity interaction with VWF
(Figure 4A,B). To exclude the possibility that the YFP moiety
contributes to FVIII targeting to WPBs, we also studied trafficking
of Tyr1680Phe and Ser2119Tyr variants in a FVIIIdB background.
Again, all FVIII variants were co-stored with VWF in WPBs
(Figure 4C). Upon FVIII co-trafficking, WPBs lose their elongated
shape and become spherical [14,15]. We have previously shown
that this shape change is specific for the presence of FVIII as co-
transfection of other WPB residents, including VWF-YFP and P-
selectin, do not result in a shape change of the WPB [15].
Interestingly, the transition from elongated to spherical WPBs was
observed for all FVIII variants, independent of their affinity for
VWF and presence of the YFP moiety (Figure 4).
FVIII-YFP Tyr1680Phe is co-stored with the VWF type 2N
variant VWF-CFP Arg763Gly
So far, our results show that targeting of FVIII variants to WPBs
is not affected by a reduced binding of these variants to VWF.
However, for most variants some residual binding to VWF is
observed. To more precisely define whether FVIII binding to
VWF is required for its targeting to WPBs, we used the previously
described VWF type 2N variant (VWF-CFP Arg763Gly) [15] in
conjunction with FVIII-YFP Tyr1680Phe. Despite a negligible
interaction in our SPR experiments (data not shown), FVIII-YFP
Tyr1680Phe was stored together with VWF-CFP Arg763Gly in
HEK293 cells (Figure 5).
Binding of FVIII-YFP to VWF is pH dependent
In the previous paragraphs we show that the impaired binding
of FVIII variants to VWF does not abolish trafficking to WPBs.
Sorting of proteins to storage organelles occurs at the levels of the
trans-Golgi network (TGN). Acidification of vesicles along the
secretory pathway provides the driving force of sorting of secretory
hormones [28]. During formation of storage granules the
intravesicular pH decreases from 6.2 to 5.5 [28]. This prompted
us to analyze the effect of pH on the interaction between VWF
and FVIII. SPR binding experiments to VWF were performed for
wild type FVIII-YFP, the Tyr1680Phe and Ser2119Tyr variant in
a pH ranging from 7.4 to 5.5. Binding of wild type FVIII-YFP was
similar over the pH range 7.4 to 6.2, but decreased at pH 5.5
(Figure 6). In agreement with the data presented in Figure 1,
binding of the FVIII-YFP variants Tyr1680Phe and Ser2119Tyr
Figure 2. Intracellular localization of FVIII-YFP variants, P-
selectin and fluorescent VWF-CFP. HEK293 cells stably expressing
VWF-CFP were transfected with P-selectin and FVIII-YFP variants. Cells
were stained for P-selectin using polyclonal anti-human CD62P
antibody. VWF-CFP, FVIII-YFP and P-selectin are shown in red, green
and blue respectively. Triple fluorescent detection is shown in the
colour merges. Shown are representative 3-dimensional projections of
Z-stacks (0.4 mm). The scale bar represents 10 mm.
doi:10.1371/journal.pone.0024163.g002
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YFP at the pH range from 7.4 to 6.2 (Figure 6). Unexpectedly,
binding of the Tyr1680Phe and Ser2119Tyr variants was
increased at pH 5.5, and proved only slightly lower than that of
wild type FVIII-YFP (Figure 6).
Discussion
Most mild and moderate hemophilia A patients can be
effectively treated with DDAVP [5]. Treatment with DDAVP
results in a concomitant increase of VWF and FVIII in the
circulation, presumably by the release of storage pools that contain
both FVIII and VWF. The formation of DDAVP-releasable co-
storage pools requires endogenous synthesis of both FVIII and
VWF. This is illustrated by the inability of DDAVP to mediate a
rise in circulating FVIII levels in patients with severe (type 3) von
Willebrand’s disease or severe hemophilia A [8,9]. Restoring
FVIII or VWF plasma levels to therapeutic levels by prophylactic
protein replacement therapy, does not result in the formation of a
DDAVP releasable co-storage pool in these patients [8,9].
Apparently, DDAVP-releasable storage pools can not be restored
by uptake of FVIII and VWF from the circulation.
While it is generally recognized that DDAVP releases VWF
from WPBs, the origin and nature of the DDAVP-sensitive storage
compartment of FVIII has not yet been defined. We and others
have proposed that the DDAVP-induced rise of both FVIII and
VWF argues for co-storage of both these proteins in WPBs.
Pertinent to this point is our recent observation that VWF type 2N
variants, despite a markedly decreased ability to bind to FVIII,
drive co-trafficking of FVIII to VWF-containing granules [15]. In
Figure 3. Quantitative analysis of storage of FVIII variants in VWF-CFP-containing organelles. HEK293 cells stably expressing VWF-CFP
were transfected with FVIII-YFP variants. (A) Cells were analyzed by Confocal Laser Scanning Microscopy. Z-stacks of 0.4 mm sections of individual cells
were acquired. A 3-dimensional reconstruction was created and the number of WPBs containing VWF and VWF/FVIII was quantified. Shown is the
mean and standard deviation of at least 7 individual cells per FVIII variant. (B–G) Representative subcellular fractionations are shown. FVIII antigen was
quantified in individual fractions by anti-FVIII light chain ELISA. The amount of FVIII light chain in fmol is plotted on the Y-axis against the fraction
number on the X-axis.
doi:10.1371/journal.pone.0024163.g003
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FVIII variant is co-stored with VWF in WPBs despite its severely
reduced interaction with VWF [13]. This raises the question as to
whether VWF co-storage of FVIII variants displaying a reduced
ability to associate with VWF represents a general phenomenon in
mild/moderate hemophilia A. We have therefore extended our
initial observation regarding the Tyr1680Phe variant to a larger
panel of mild/moderate hemophilia A causing FVIII variants,
including amino acid replacements in the FVIII C1 and C2
domains. In addition, we now have used a quantitative approach
to assess trafficking of FVIII to VWF-containing granules in
HEK293 cells. Moreover, we addressed co-trafficking of GFP-
tagged as well as untagged FVIII variants in endothelial cells, with
particular reference to the morphology of FVIII-containing WPBs.
We demonstrate that point mutations in the C1 and C2
domains of FVIII can have diverse effects on its synthesis,
secretion and ability to bind to VWF without loss in cofactor
function, in agreement with previously published data [21]. The
ranking of VWF binding is the following: wild type.Ar-
g2150His.Del2201.Pro2300Ser.Ser2119Tyr=Tyr1680Phe
(Figure 1). Remarkably, notwithstanding their reduced capac-
ity to bind to VWF and/or reduced levels of synthesis,
substantial amounts of moderate/mild hemophilia A causing
FVIII variants can be stored in VWF-containing granules
(Figures 2, 3, 4). Our quantitative studies showed that,
independent of the amino acid replacement, relative amounts
of FVIII stored in VWF-containing granules are similar
(Figure 3). Assuming that co-expression and co-storage of
FVIII and VWF does occur in vivo, our data provide a
molecular explanation for the fact that hemophilia A patients
suffering from impaired complex assembly of FVIII and VWF
in the circulation can be effectively treated with DDAVP. In
particular, hemophilia A patients carrying a Tyr1680Phe,
Ser2119Tyr, Arg2150His replacement or deletion of Ala2201,
respond to DDAVP treatment by a concomitant increase of
FVIII and VWF [22,29]. In previous studies FVIII has been
expressed in VWF-containing a-granules in mice. In this
model, the benefit of FVIII release concomitant with platelet
activation was convincingly demonstrated [30,31]. Recently,
targeting of FVIII to WPBs has been shown to restore
hemostasis in a mouse model of hemophilia A [32]. This
finding further emphasizes the hemostatic potential of
DDAVP-induced FVIII release from WPBs.
The mechanism of FVIII/VWF co-storage in WPBs has not
been elucidated so far. It seems logical to suppose that FVIII
targets to the WPBs by virtue of a direct interaction with VWF
Table 2. Subcellular fractionation of transfected HEK293 cells.
FVIII-YFP Percentage VWF Percentage FVIII
variant
fractions 4–9 fractions 4–9
wild type 16652 1 66
Tyr1680Phe 16651 4 66
Ser2119Tyr 19661 6 64
Arg2150His 18641 6 68
Del2201 16651 7 64
Pro2300Ser 21641 8 611
HEK293 cells stably expressing VWF-CFP were transfected with FVIII-YFP
variants. FVIII antigen was quantified by anti-FVIII light chain ELISA. VWF
antigen was quantified by ELISA. The amount of FVIII and VWF antigen in the
pooled fractions 4–9 is divided by the total amount of FVIII and VWF antigen in
the pooled fractions 1–25. The values represent the mean 6 SD of three
measurements.
doi:10.1371/journal.pone.0024163.t002
Figure 4. Co-trafficking of FVIII variants to Weibel-Palade
bodies in endothelial cells. Human BOEC passage 8 were
transduced with lentiviral vectors encoding (A) FVIII-YFP, (B) FVIII-YFP
variants carrying Tyr1680Phe, Del 2201, Ser2119Tyr, Arg2150His and
Pro2300Ser replacements or (C) FVIIIdB wild type and variants carrying
Tyr1680Phe or Ser2119Tyr replacements. Cells were stained for VWF
using monoclonal antibody CLB-RAg20, shown in red (A,B,C) and for
FVIIIdB (variants) (C) using FITC-labelled monoclonal antibody EL14
IgG4. FVIII-YFP and FVIII dB (variants) are shown in green. Double
fluorescent detection is shown in the colour merges. Shown are
representative 3-dimensional projections of Z-stacks (0.4 mm). The scale
bar represents 20 mm.
doi:10.1371/journal.pone.0024163.g004
Figure 5. Co-storage of FVIII-YFP Tyr1680Phe with VWF type
2N variant VWF-CFP Arg763Gly. HEK293 cells stably expressing
FVIII-YFP Tyr1680Phe were transfected with VWF-CFP Arg763Gly. Cells
were stained for the trans-Golgi network using polyclonal antibody
TGN46. Triple fluorescent detection is shown in the colour merge.
Shown is a representative 3-dimensional projection of Z-stack (0.4 mm).
The scale bar represents 10 mm.
doi:10.1371/journal.pone.0024163.g005
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secretory pathway, the pH decreases from pH 7.4 in the ER, to
pH 6.2 in the Golgi, to pH 5.5 in mature secretory granules [28].
This acidification process is essential for sorting and processing of
regulated secretory hormones [28]. In endothelial cells, a
decreasing pH along the secretory pathway has been postulated
to mediate WPB biogenesis by coordinating the disulfide-linked
assembly of VWF multimers and their tubular packing [33]. At
pH 6.2, intersubunit disulfide bond formation between VWF
propeptide and D’D3 dimers results in the generation of helical
tubules [33] which most likely underlies the biogenesis of
elongated WPBs [34]. It has been suggested that histidine residues
in the propeptide function as pH sensors and control the disulfide
bond formation within D’D3 [35].
We observed that the FVIII Tyr1680Phe and Ser2119Tyr
variants bind better to VWF under acidic conditions (Figure 6).
This indicates that FVIII can bind to VWF in multiple ways,
including high-affinity interaction with a pH optimum of 6.7 and
low-affinity interaction with a pH optimum of 5.5 or lower. At first
sight, these data suggest that pH-dependent binding of FVIII and
VWF along the secretory pathway may drive co-targeting of FVIII
to WPBs suggesting that ‘histidine switch’ may also control entry of
FVIII in WPBs. However, targeting of proteins to the secretory
pathway is thought to occur at the trans-Golgi network where
intracellular conditions are intermediate between ER and
secretory organelles, pH 6.2. In endothelial cells, the pH has
been described to be 5.4560.26 for resting WPBs and 6.1660.45
for newly formed WPBs [36]. The latter WPBs, which presumably
have just been pinched off from the trans-Golgi network, thus are
just in the pH range wherein the changes in pH-dependent VWF-
FVIII interaction occur. While this would explain that FVIII and
VWF may be associated within WPBs, it remains unclear whether
or not this would be sufficient for association of FVIII and VWF
within the secretory pathway during WPB biogenesis. Our data
seem equally compatible with the existence of an alternative,
VWF-independent targeting mechanism. It remains difficult to
Figure 6. pH dependent binding of FVIII-YFP variants to VWF. FVIII-YFP (black), FVIII-YFP Tyr1680Phe (red) and FVIII-YFP Ser2119Tyr (blue)
(7.5–90 nM) were passed over various densities (23–39 fmol/mm
2) of immobilized recombinant wild type VWF in buffers containing 150 mM NaCl,
5 mM CaCl2, 0.005% (v/v) Tween 20 and 20 mM Hepes (pH 7.4 and 6.7) or 20 mM MES (pH 6.2 and 5.5). The response at 235 seconds of association
was expressed per amount of VWF immobilized on the SPR chip and plotted against the concentration of FVIII-YFP variants. Values represent the
mean 6 standard deviation for the three different VWF densities.
doi:10.1371/journal.pone.0024163.g006
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with a VWF type 2N variant that is severely defective in
interacting with FVIII [15], still leads to co-storage with VWF
(Figure 5). Both the pH-dependent FVIII-VWF association and
the possibility of a VWF-independent targeting mechanism remain
intriguing issues for further study.
Materials and Methods
Plasmid mutagenesis
Construction of wild type VWF [13], VWF-CFP with the Cyan
Fluorescent Protein moiety replacing the A2 domain and VWF-
CFP Arg763Gly [13], B-domain deleted (del 746–1639) FVIII-
YFP with the Yellow Fluorescent Protein moiety replacing the B-
domain (FVIII-YFP) [13] and P-selectin [37] in pcDNA3.1(+)
have been described previously. Point mutations and deletions in
FVIII-YFP were introduced by Quick Change mutagenesis
TM
(Table S1). B-domain deleted FVIII variants lacking the YFP
moiety (FVIIIdB) were created by removal of the YFP moiety by
Quick Change mutagenesis
TM (Table S1). FVIII-YFP variants and
B-domain deleted FVIII variants were ligated into the lentiviral
self-inactivating vector under control of the CAG promoter
consisting of the chicken b-actin promoter, CMV enhancers and
a large synthetic intron [14] using NheI and NotI. The coding
regions of all constructs were verified by sequence analysis.
Sequence reactions were performed with BigDye Terminator
Sequencing kit (Applied Biosystems, Foster City, CA, USA).
Expression and purification of recombinant proteins
HEK293 cells (CRL-1573) (ATCC, Manassas, VA, USA) were
grown in DMEM-F12 medium supplemented with 10% FCS,
100 units/ml penicillin and 100 mg/ml streptomycin (BioWhit-
tacker, Verviers, Belgium). HEK293 cell-lines, stably expressing
recombinant protein were produced as described [38]. Recombi-
nant VWF containing high molecular weight multimers and FVIII
variants were purified and analyzed as described [13].
Binding of FVIII-YFP variants to VWF
Pseudo-equilibrium binding of FVIII variants to VWF using an
ELISA-based format was performed and analyzed as described
[13]. Association and dissociation of FVIII variants to wild type
VWF was assessed by Surface Plasmon Resonance (SPR) analysis
employing a BIAcore 3000 biosensor (Biacore AB, Uppsala,
Sweden) [15]. Recombinant wild type VWF, VWF-CFP or VWF-
CFP Arg763Gly (22 fmol/mm
2) was immobilized onto a CM5
sensor chip using the amine coupling method according to the
manufacturer’s instructions. Binding to coated channels was
corrected for binding in absence of VWF. Varying concentrations
(1–15 nM) of FVIII-YFP variants were passed over the immobi-
lized VWF in a buffer containing 150 mM NaCl, 5 mM CaCl2,
5% (v/v) Glycerol, 0.005% (v/v) Tween 20 and 20 mM Hepes
(pH 7.4) at 25uC with a flow rate of 20 mL/min. The sensor chip
surface was regenerated using the same buffer containing 1 M
NaCl. To study the influence of pH on the interaction between
VWF and FVIII (variants), wild type VWF was immobilized onto
a CM5 sensor chip at various densities (23–39 fmol/mm
2) and
FVIII-YFP variants (Tyr1680Phe and Ser2119Tyr) were passed
over the immobilized wild type VWF in buffers containing
150 mM NaCl, 5 mM CaCl2, 0.005% (v/v) Tween 20 and
20 mM Hepes (pH 7.4 or 6.7) or 20 mM MES (pH 6.2 or 5.5).
Expression levels of FVIII-YFP variants
HEK293 cells stably expressing VWF-CFP were transfected
using the calcium phosphate co-precipitation method essentially as
described [39]. Briefly, 2.5610
5 cells/10 cm
2 were seeded
24 hours before transfection on a gelatine-coated culture surface.
Medium was refreshed 4 hours before transfection. Cells were
transfected using 5 mg of plasmid DNA. Medium was refreshed
16 hours after transfection and cells were grown for an additional
72 hours. Antigen levels were determined by heterodimer ELISA
[40] using CLB-CAg9 and CLB-CAg117. Activity levels were
determined by chromogenic assay. Human pooled plasma from at
least 30 donors, calibrated against the 5
th International Standard
for FVIII and VWF in plasma (WHO 02/150), was used as a
standard.
Immunofluorescence analysis
HEK293 cells stably expressing VWF-CFP or FVIII-YFP
Tyr1680Phe were transfected using the calcium phosphate co-
precipitation method [39]. Blood outgrowth endothelial cells
(BOECs) were isolated as described previously [14] from 50 ml of
venous blood that was drawn from healthy anonymous volunteers,
with written permission, in accordance with Dutch regulations and
approval from Sanquin Ethical Advisory Board. Lentiviral
preparations of FVIII variants were produced and BOECs were
transduced as described [14]. Cells were prepared for immuno-
fluorescence as described before [41]. Rabbit polyclonal antibody
anti-human CD62-P (BD PharMingen, San Diego, CA, USA) was
used to visualize P-selectin and sheep polyclonal antibody TGN46
(Serotec, Oxford, United Kingdom) was used to stain the trans-
Golgi network. VWF was stained using monoclonal antibody
CLB-RAg20 and FVIIIdB (variants) were stained using FITC-
labeled human monoclonal antibody EL14 IgG4 [15]. Alexa-594
and Alexa-633- conjugated secondary antibodies were from
Invitrogen (Breda, the Netherlands). Confocal Laser Scanning
Microscopy was performed using a Zeiss LSM510 (Carl Zeiss,
Heidelberg, Germany). For immunohistochemical analysis results
were analyzed using Zeiss LSM510 version 4.0 software (Carl
Zeiss, Heidelberg, Germany) or Image J (freely available through
http://rsbweb.nih.gov/ij/). To obtain 3-dimensional images, Z-
stacks of 0.4 mm sections of individual cells were acquired. A 3-
dimensional reconstruction was created with Image Pro Plus 6.0
(Media Cybernetics, Breda, the Netherlands) and used to calculate
the number of Weibel-Palade bodies within individual cells. In
order to separate narrowly connected Weibel-Palade bodies, the
3D Watershed filter (threshold 10%) was applied. The number of
Weibel-Palade bodies containing VWF and VWF/FVIII was
quantified by using the volume measurements software in the 3D
constructor module. Results were analyzed using GraphPad Prism
4 software.
Subcellular fractionation
HEK293 cells stably expressing VWF-CFP or wild type VWF
were transfected using 87.5 mg plasmid DNA per 175 cm
2 flask as
described above. Per FVIII variant, two 175 cm
2 culture flasks
were transfected. Subcellular fractionation using Percoll density
gradient centrifugation was performed as described with minor
modifications [42]. Briefly, cells were homogenized by 20 strokes
in a ball-bearing homogenizer (Isobiotec, Heidelberg, Germany)
with a 14 micron clearance. The homogenate was loaded on a
Percoll gradient and centrifuged for 30 minutes at 100,000 g and
4uC. Fractions (1.25 ml) were collected from the bottom and
stored at 220 uC. FVIII antigen was quantified by anti-light chain
ELISA as described above. VWF antigen was quantified by
ELISA essentially as described before [43]. Individual fractions
were measured as well as pooled fractions 4–9 (dense fractions)
and pooled fractions 1–25 (total).
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